GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Cyclically Adjusted Price-to-FCF

Bruker (Bruker) Cyclically Adjusted Price-to-FCF : 66.37 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Bruker Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Bruker's current share price is $80.97. Bruker's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $1.22. Bruker's Cyclically Adjusted Price-to-FCF for today is 66.37.

The historical rank and industry rank for Bruker's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BRKR' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 33.02   Med: 52.21   Max: 98.24
Current: 66.52

During the past years, Bruker's highest Cyclically Adjusted Price-to-FCF was 98.24. The lowest was 33.02. And the median was 52.21.

BRKR's Cyclically Adjusted Price-to-FCF is ranked worse than
72.49% of 229 companies
in the Medical Devices & Instruments industry
Industry Median: 42.33 vs BRKR: 66.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Bruker's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $1.189. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.22 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bruker Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Bruker's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Cyclically Adjusted Price-to-FCF Chart

Bruker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.37 66.98 86.24 62.82 60.36

Bruker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.82 67.15 61.72 52.01 60.36

Competitive Comparison of Bruker's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Bruker's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bruker's Cyclically Adjusted Price-to-FCF falls into.



Bruker Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Bruker's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=80.97/1.22
=66.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bruker's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Bruker's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.189/129.4194*129.4194
=1.189

Current CPI (Dec. 2023) = 129.4194.

Bruker Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.055 99.695 0.071
201406 0.032 100.560 0.041
201409 0.021 100.428 0.027
201412 0.367 99.070 0.479
201503 0.126 99.621 0.164
201506 -0.054 100.684 -0.069
201509 0.265 100.392 0.342
201512 0.817 99.792 1.060
201603 -0.134 100.470 -0.173
201606 0.055 101.688 0.070
201609 0.168 101.861 0.213
201612 0.496 101.863 0.630
201703 0.131 102.862 0.165
201706 -0.167 103.349 -0.209
201709 0.158 104.136 0.196
201712 0.583 104.011 0.725
201803 0.225 105.290 0.277
201806 0.173 106.317 0.211
201809 0.102 106.507 0.124
201812 0.712 105.998 0.869
201903 0.023 107.251 0.028
201906 -0.047 108.070 -0.056
201909 0.233 108.329 0.278
201912 0.695 108.420 0.830
202003 0.029 108.902 0.034
202006 -0.055 108.767 -0.065
202009 0.420 109.815 0.495
202012 1.131 109.897 1.332
202103 0.478 111.754 0.554
202106 -0.005 114.631 -0.006
202109 0.050 115.734 0.056
202112 0.722 117.630 0.794
202203 0.388 121.301 0.414
202206 -0.416 125.017 -0.431
202209 0.079 125.227 0.082
202212 0.926 125.222 0.957
202303 0.423 127.348 0.430
202306 -0.071 128.729 -0.071
202309 0.117 129.860 0.117
202312 1.189 129.419 1.189

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bruker  (NAS:BRKR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Bruker Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Bruker's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bruker (Bruker) Business Description

Traded in Other Exchanges
Address
40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
Executives
Frank H Laukien director, 10 percent owner, officer: CEO, President C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer director 9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch officer: Pres. Bruker Nano Inc. BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega officer: Group President Bruker CALID BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause officer: Pres. & CEO, Bruker EST BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse officer: President, BioSpin Group 40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman officer: Vice President, Corp Contr. 55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139